UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 58,807 Shares of LivaNova PLC (NASDAQ:LIVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 92.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 122,740 shares of the company's stock after acquiring an additional 58,807 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.23% of LivaNova worth $6,449,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Fifth Third Bancorp raised its position in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after purchasing an additional 332 shares during the period. Canada Pension Plan Investment Board acquired a new stake in LivaNova during the 2nd quarter worth approximately $88,000. Central Pacific Bank Trust Division bought a new stake in LivaNova in the 3rd quarter valued at $178,000. TradeLink Capital LLC acquired a new position in LivaNova in the 2nd quarter valued at $208,000. Finally, GSA Capital Partners LLP bought a new position in LivaNova during the 3rd quarter worth $292,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group began coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price for the company. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Needham & Company LLC reissued a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. Finally, StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $69.17.

LivaNova Price Performance

Shares of LIVN stock traded up $1.45 during trading hours on Wednesday, reaching $51.49. The company's stock had a trading volume of 874,520 shares, compared to its average volume of 608,090. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The firm's 50 day simple moving average is $52.04 and its 200-day simple moving average is $51.60. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of 122.60 and a beta of 0.98.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.